LAUSR

Skeletal muscle insulin resistance is a hallmark of individuals with type 2 diabetes mellitus (T2D). In healthy individuals insulin stimulates vasodilation, which is markedly blunted in T2D; however, the mechanism(s) remain incompletely understood. Investigations in rodents indicate augmented endothelin-1 (ET-1) action as a major contributor. Human studies have been limited to young obese participants and focused exclusively on the ET-1 A (ETA) receptor. Herein, we hypothesized that ETA receptor antagonism would improve insulin-stimulated vasodilation and glucose uptake in T2D, with further improvements observed during concurrent ETA + ET-1 B (ETB) antagonism. Arterial pressure (arterial line), leg blood flow (LBF; Doppler) and leg glucose uptake (LGU) were measured at rest, during hyperinsulinemia alone, and hyperinsulinemia with 1) femoral artery infusion of BQ-123, the selective ETA receptor antagonist (N=10 control, N=9 T2D) and then 2) addition of BQ-788 (selective ETB antagonist) for blockade of ETA and ETB receptors (n=7 each). The LBF responses to hyperinsulinemia alone tended to be lower in T2D (Controls: ∆161 ± 160 mL/min; T2D: ∆58 ± 43 mL/min, P=0.08). BQ-123 during hyperinsulinemia augmented LBF to a greater extent in T2D (%change: Controls: 14 ± 23%; T2D: 38 ± 21%, P=0.029). LGU following BQ-123 increased similarly between groups (P=0.85). Concurrent ETA + ETB antagonism did not further increase LBF or LGU in either group. Collectively, these findings suggest that during hyperinsulinemia ETA receptor activation restrains vasodilation more in T2D than controls while limiting glucose uptake similarly in both groups, with no further effect of ETB receptors (NCT04907838).